Risk Factors for Death of Patients with Cystic Fibrosis Awaiting Lung Transplantation
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Rationale: The optimal timing for listing of cystic fibrosis patients for lung transplantation is controversial. Objectives: We conducted a retrospective cohort study of 343 patients listed for lung transplantation at four academic medical centers to identify risk factors for death while awaiting transplantation. Methods: Data on possible risk factors were abstracted from medical records. Measurements: Time to death, patient demographic characteristics, and risk factors for death while awaiting transplantation were assessed. Univariate and multivariate survival analyses were performed using Cox regression. Results: By univariate analyses, FEV1 ⩽ 30% predicted (HR, 3.8; 95% CI, 2.0–7.5), PaCO2 ⩾ 50 mm Hg (HR, 1.85; 95% CI, 1.1–3.0), and shorter height (HR, 1.8; 95% CI, 1.1–3.0) were associated with a higher risk of death. Referral from an accredited cystic fibrosis center was associated with a lower risk (HR, 0.53; 95% CI, 0.30–0.92). The final multivariate model included referral from an accredited cystic fibrosis center (HR, 0.5; 95% CI, 0.3–1.0) and listing year after 1996 (HR, 0.4; 95% CI, 0.2–0.7); both were associated with a lower risk of death. FEV1 ⩽ 30% predicted (HR, 6.8; 95% CI, 2.4–19.3), PaCO2 ⩾ 50 mm Hg (HR, 6.9; 95% CI, 1.5–32.1), and use of a nutritional intervention (HR, 2.3; 95% CI, 1.3–4.1) were associated with increased risk. Patients with FEV1 > 30% predicted had a higher risk of death only when their PaCO2 was ⩾ 50 mm Hg (HR, 7.0; 95% CI, 1.5–32), while the increased risk of death with FEV1 ⩽ 30% was not further influenced by the presence of hypercapnia. Conclusions: We identified risk factors for waiting list mortality that could impact on transplant listing and allocation guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additional risk factors for mortality in those with severely compromised lung function include FEV1< 25% predicted, rapid decline in FEV1, PaCO2 > 50mmHg, impaired functional status, and pulmonary hypertension. (244, 246–251)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [248]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
Modelling for Survival Data in Medical Research
(1995) · Technometrics · doi:10.1080/00401706.1995.10485920 · Cited by 2,145
Prediction of mortality in patients with cystic fibrosis
Kerem, E., Reisman, J., Corey, M., Canny, G. J., & Levison, H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204303261804 · Cited by 993 · cited 4×
“An FEV1 of less than 30% predicted has been the guidepost for referral for lung transplantation, based on the landmark study published by Kerem and coworkers (3).”
BackgroundResultInfluentialCorey, M., McLaughlin, F. J., Williams, M., & Levison, H. (1988) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(88)90063-7 · Cited by 815
Predictive 5-year survivorship model of cystic fibrosis
Liou, T. G., Adler, F. R., FitzSimmons, S. C., Cahill, B. C., Hibbs, J. R., & Marshall, B. C. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.4.345 · Cited by 749
The Prognostic Value of Exercise Testing in Patients with Cystic Fibrosis
Nixon, P. A., Orenstein, D. M., Kelsey, S. F., & Doershuk, C. F. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212173272504 · Cited by 631
International guidelines for the selection of lung transplant candidates
Maurer, J. R., Frost, A. E., Estenne, M., Higenbottam, T., & Glanville, A. R. (1998) · Transplantation · doi:10.1097/00007890-199810150-00033 · Cited by 562
Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease
Hosenpud, J. D., Bennett, L. E., Keck, B. M., Edwards, E. B., & Novick, R. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)06405-2 · Cited by 472
Arcasoy, S. M., & Kotloff, R. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904083401406 · Cited by 443
Self-citationGender Gap in Cystic Fibrosis Mortality
Rosenfeld, M., Davis, R., FitzSimmons, S., Pepe, M., & Ramsey, B. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009172 · Cited by 366
Research works printed but not linked: 6
- 2001, Pediatr Pulmonol, 32, 317
- 2004, Pediatr Pulmonol, 38, 317
- 1998, J Heart Lung Transplant, 17, 703
- 1997, J Heart Lung Transplant, 16, 313
- 2001, J Heart Lung Transplant, 20, 242
- 2001, Eur J Med Res, 6, 345
Cited by
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Self-citationRamos, K. J., Smith, P. J., McKone, E. F., Pilewski, J. M., Lucy, A., Hempstead, S. E., Tallarico, E., Faro, A., Rosenbluth, D. B., Gray, A. L., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.03.002 · Cited by 227
Association between Pulmonary Function and Sputum Biomarkers in Cystic Fibrosis
Mayer-Hamblett, N., Aitken, M. L., Accurso, F. J., Kronmal, R. A., Konstan, M. W., Burns, J. L., Sagel, S. D., & Ramsey, B. W. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200609-1354oc · Cited by 226
PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy
Osman, G., Rodriguez, J., Chan, S. Y., Chisholm, J., Duncan, G., Kim, N., Tatler, A. L., Shakesheff, K. M., Hanes, J., Suk, J. S., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.001 · Cited by 208
Elevated CO2 Levels Cause Mitochondrial Dysfunction and Impair Cell Proliferation
Vohwinkel, C. U., Lecuona, E., Sun, H., Sommer, N., Vadász, I., Chandel, N. S., & Sznajder, J. I. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.290056 · Cited by 176
Metadata
- Authors
- Belkin, R. A., Henig, N. R., Singer, L. G., Chaparro, C., Rubenstein, R. C., Xie, S. X., Yee, J. Y., Kotloff, R. M., Lipson, D. A., & Bunin, G. R.
- Affiliations
- University Health Network (CA)
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-03
- Volume
- 173
- Issue
- 6
- Pages
- 659-666
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC2662949
- OpenAlex
- W2045873707
- Cited by
- 180
- References
- 40
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 9 · 2022: 3 · 2021: 11 · 2020: 10 · 2019: 12 · 2018: 15 · 2017: 10 · 2016: 10 · 2015: 12 · 2014: 9 · 2013: 13 · 2012: 12
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cystic Fibrosis Foundation
- National Institutes of Health (1f32hl074534-01)
- National Heart, Lung, and Blood Institute (F32 HL74534-01)
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Neonatal Respiratory Health Research
- Keywords
- cystic fibrosis, lung transplantation, transplant listing, mortality risk factors, hypercapnia, FEV1, hypercapnic respiratory failure, dietary intervention, waiting lists
- MeSH terms
- Adult, Cause of Death, Child, Cystic Fibrosis, Female, Follow-Up Studies, Forced Expiratory Volume, Humans, Male, Prognosis, Retrospective Studies, Risk Factors, Severity of Illness Index, Waiting Lists, Survival Rate, Proportional Hazards Models, Lung Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk Factors for Death of Patients with Cystic Fibrosis Awaiting Lung Transplantation. https://app.cochat.ai/papers/10.1164/rccm.200410-1369oc
- The paper
- Belkin, R. A., Henig, N. R., Singer, L. G., Chaparro, C., Rubenstein, R. C., Xie, S. X., Yee, J. Y., Kotloff, R. M., Lipson, D. A., & Bunin, G. R. (2006). Risk Factors for Death of Patients with Cystic Fibrosis Awaiting Lung Transplantation. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200410-1369oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.